Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial
Natàlia Casamitjana, Marc Corbacho-Monné, María Ubals, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 11, pp. e4073-e4081
Open Access | Times Cited: 278

Showing 26-50 of 278 citing articles:

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul, Emil Eik Nielsen, Joshua Feinberg, et al.
PLoS Medicine (2020) Vol. 17, Iss. 9, pp. e1003293-e1003293
Open Access | Times Cited: 84
TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection
Allison M. Owen, Jessica B. Fults, Naeem K. Patil, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 84
COVID-19 Therapeutic Options Under Investigation
Malak Kaddoura, Malak Al Ibrahim, Ghina Hijazi, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 83
Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
Abdulrahman E. Koshak, Emad A. Koshak, Abdullah F. Mobeireek, et al.
Complementary Therapies in Medicine (2021) Vol. 61, pp. 102769-102769
Open Access | Times Cited: 79
COVID-19—Lessons Learned and Questions Remaining
Ferric C. Fang, Constance A. Benson, Carlos del Rı́o, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 12, pp. 2225-2240
Open Access | Times Cited: 76
Hydroxychloroquine and COVID-19: a Rheumatologist’s Take on the Lessons Learned
Akrithi Udupa, David Leverenz, Stephen J. Balevic, et al.
Current Allergy and Asthma Reports (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 65
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
Jialing Yin, Chengcheng Li, Chunhong Ye, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 824-837
Open Access | Times Cited: 64
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
Christine Johnston, Elizabeth R. Brown, Jenell Stewart, et al.
EClinicalMedicine (2021) Vol. 33, pp. 100773-100773
Open Access | Times Cited: 62
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial
Jean‐Jacques Parienti, Thiérry Prazuck, Laure Peyro‐Saint‐Paul, et al.
EClinicalMedicine (2021) Vol. 38, pp. 100993-100993
Open Access | Times Cited: 56
NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders?
Annabell Roberti, Laura Elizabeth Chaffey, David R. Greaves
Biology (2022) Vol. 11, Iss. 3, pp. 372-372
Open Access | Times Cited: 44
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 33
Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis
Karen M Elias, Shanchita R. Khan, Eva Stadler, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 5, pp. e459-e467
Open Access | Times Cited: 10
The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis
Shivani Singh, Simon Boyd, William HK Schilling, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 5, pp. 935-945
Open Access | Times Cited: 7
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
Philip L. Tzou, Kaiming Tao, Janin Nouhin, et al.
Viruses (2020) Vol. 12, Iss. 9, pp. 1006-1006
Open Access | Times Cited: 68
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Christopher T. Rentsch, Nicholas DeVito, Brian MacKenna, et al.
The Lancet Rheumatology (2020) Vol. 3, Iss. 1, pp. e19-e27
Open Access | Times Cited: 67
Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19
Ali S. Omrani, Sameer A. Pathan, Sarah A. Thomas, et al.
EClinicalMedicine (2020) Vol. 29-30, pp. 100645-100645
Open Access | Times Cited: 66
Pregnancy and COVID‐19: pharmacologic considerations
Rohan D’Souza, Rabia Ashraf, H. Rowe, et al.
Ultrasound in Obstetrics and Gynecology (2020) Vol. 57, Iss. 2, pp. 195-203
Open Access | Times Cited: 64
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
Abdullahi Rabiu Abubakar, Ibrahim Sani, Brian Godman, et al.
Infection and Drug Resistance (2020) Vol. Volume 13, pp. 4673-4695
Open Access | Times Cited: 61
A Comprehensive Overview of the COVID-19 Literature: Machine Learning–Based Bibliometric Analysis
Alaa Abd‐Alrazaq, Jens Schneider, Borbála Mifsud, et al.
Journal of Medical Internet Research (2020) Vol. 23, Iss. 3, pp. e23703-e23703
Open Access | Times Cited: 57
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 56
Pandemics and Traditional Plant-Based Remedies. A Historical-Botanical Review in the Era of COVID19
Sònia Garcia
Frontiers in Plant Science (2020) Vol. 11
Open Access | Times Cited: 55
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine
Bianza Moïse Bakadia, Feng He, Tiatou Souho, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 133, pp. 111008-111008
Open Access | Times Cited: 53
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
Andrew Ip, Jaeil Ahn, Yizhao Zhou, et al.
BMC Infectious Diseases (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 53
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
Cardiovascular Research (2021) Vol. 118, Iss. 7, pp. 1618-1666
Open Access | Times Cited: 52

Scroll to top